113 HR 1429 IH: Scleroderma Research and Awareness Act of 2013 U.S. House of Representatives 2013-04-09 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I 113th CONGRESS 1st Session H. R. 1429 IN THE HOUSE OF REPRESENTATIVES April 9, 2013 Mrs. Capps (for herself and Mr. King of New York) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To expand the research and awareness activities of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the Centers for Disease Control and Prevention with respect to scleroderma, and for other purposes.

1.

Short title

This Act may be cited as the Scleroderma Research and Awareness Act of 2013.

2.

National institute of arthritis and musculoskeletal and skin diseases; scleroderma research expansion

Part B of title IV of the Public Health Service Act (42 U.S.C. 284 et seq.) is amended by adding at the end the following:

409K.

Scleroderma research

The Director of NIH may expand, intensify, and coordinate the activities of the National Institutes of Health with respect to scleroderma, with particular emphasis on the following: (1)Research focused on the etiology of scleroderma and the development of new treatment options. (2)Clinical research to evaluate new treatments options. (3)Basic research on the relationship between scleroderma and secondary conditions such as pulmonary hypertension, gastroparesis, Raynaud's phenomenon, Sjögren's Syndrome, and other diseases as determined by the Director.

.

3.

Promoting public awareness of scleroderma

Part P of title III of the Public Health Service Act (42 U.S.C. 280g et seq.) is amended by adding at the end the following:

399V–6.

Promoting public awareness of scleroderma

The Secretary may carry out an educational campaign to increase public awareness of scleroderma. Print, video, and Web-based materials distributed through this campaign may include— (1)basic information on scleroderma and its symptoms; and (2)information on— (A)the incidence and prevalence of scleroderma; (B)diseases and conditions affiliated with scleroderma; or (C)the importance of early diagnosis and treatment of scleroderma.

.